Active Biotech AB, of Lund, Sweden, and Ipsen SA, of Paris, presented new data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate-resistant prostate cancer (CRPC...Aragon Pharmaceuticals Inc., of San Diego, presented data from an ongoing Phase II trial showing that ARN-509, its second-generation androgen receptor antagonist, demonstrated promising results in three separate patient populations with castration-resistant prostate cancer

In castrate-resistant prostate cancer, the Phase III study called SYNERGY is expected to complete enrollment later this year...Results showed a higher number of prostate cancer patients taking OGX-427 plus prednisone without disease progression at 12 weeks (71 percent), compared with those taking prednisone alone (40 percent

The study is being conducted in European men with metastatic castrate-resistant prostate cancer to describe product-release parameters and report on safety in a European population...Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., opened enrollment in a Phase II study in prostate cancer patients of its PSMA ADC compound

facilities in preparation to launch its prostate cancer drug Alpharadin, which is partnered with Leverkusen, Germany-based Bayer AG...In the trial, escalating doses of APR-246 were administered as a monotherapy to 22 patients with advanced blood or prostate cancer for up to four consecutive days

Besides NSCLC, Peregrine is in earlier trials testing bavituximab in combination with chemotherapy in pancreatic cancer, hepatocellular carcinoma, castration-resistant prostate cancer, HER2-negative metastatic breast cancer and rectal adenocarcinoma

Simultaneously, a group from the University of California at San Francisco reported that, as the title of their paper summarized succinctly, "In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer...18, 2012, online edition of mBIO, while the paper on prostate cancer was published in the Sept

NewLink Genetics Inc., of Ames, Iowa, said it will start a Phase II study testing its IDO pathway inhibitor, indoximod (D-1MT/NLG8189), in combination with Provenge (sipuleucel-T) in patients with asymptomatic or minimally symptomatic metastatic hormone-refractory prostate cancer

Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said the independent data monitoring committee for the Phase II study of NX-1207 in low-risk localized prostate cancer reported a positive interim analysis from the first group of patients to receive either a high- or low-dose of the drug

facilities in preparation to launch its prostate cancer drug Alpharadin, which is partnered with Leverkusen, Germany-based Bayer AG

In an open-label Phase I/IIa trial in 44 patients with castrate-resistant prostate cancer and rising levels of PSA, CV9103 elicited an immune response against at least one antigen in 79 percent of the patients, and against more than one antigen in 58 percent of the responding patients...Seattle-based Dendreon Corp.'s autologous cell therapy for prostate cancer Provenge (sipuleucel-T) was the first therapeutic cancer vaccine to gain approval, but its commercial performance has not matched

In the trial, escalating doses of APR-246 were administered as a monotherapy to 22 patients with advanced blood or prostate cancer for up to four consecutive days

Tuebingen, Germany-based CureVac plans to move its prostate cancer vaccine, CV9103, into a European Phase IIb trial shortly, but a readout will not be available until 2016 or 2017, CEO Ingmar Hoerr, told BioWorld Today...Seattle-based Dendreon Corp.'s autologous cell therapy for prostate cancer Provenge (sipuleucel-T) was the first therapeutic cancer vaccine to gain approval, but its commercial performance has not matched expectations, owing to its high price and difficult logistics

Astellas Pharma Inc., of Tokyo, and Medivation Inc., of San Francisco, said Xtandi (enzalutamide) capsules are available for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel

In an open-label Phase I/IIa trial in 44 patients with castrate-resistant prostate cancer and rising levels of PSA, CV9103 elicited an immune response against at least one antigen in 79 percent of the patients, and against more than one antigen in 58 percent of the responding patients...Seattle-based Dendreon Corp.'s autologous cell therapy for prostate cancer Provenge (sipuleucel-T) was the first therapeutic cancer vaccine to gain approval, but its commercial performance has not matched

In a 2011 meeting to discuss prostate cancer endpoints, the FDA asked for the committee's endpoint on trial designs with endpoints such as asymptomatic metastasis-free survival, and symptomatic metastasis-free survival, as well as OS

IRX4204 has been tested in Phase I/II trials in solid tumors and is currently being evaluated in a Phase II trial in advanced prostate cancer

Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, said Xtandi (enzalutamide) capsules are available for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel

Astex Pharmaceuticals Inc., of Dublin, Calif., said it started a Phase I/II trial of Hsp90 inhibitor AT13387 in castration-resistant prostate cancer (CRPC) patients who are no longer responding to standard-of-care therapies Zytiga (abiraterone acetate, Johnson & Johnson) and steroids

received FDA approval for Xtandi (enzalutamide) capsules for prostate cancer